Atlantic Union Bankshares Corp Has $13.48 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Atlantic Union Bankshares Corp grew its position in Pfizer Inc. (NYSE:PFE) by 177.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 311,107 shares of the biopharmaceutical company’s stock after purchasing an additional 198,898 shares during the period. Pfizer comprises about 1.8% of Atlantic Union Bankshares Corp’s holdings, making the stock its 10th largest position. Atlantic Union Bankshares Corp’s holdings in Pfizer were worth $13,477,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PFE. WBI Investments Inc. bought a new stake in Pfizer during the 2nd quarter valued at approximately $2,760,000. Landsberg Bennett & Dubbaneh LLC lifted its position in shares of Pfizer by 6.7% in the 2nd quarter. Landsberg Bennett & Dubbaneh LLC now owns 86,757 shares of the biopharmaceutical company’s stock worth $3,797,000 after acquiring an additional 5,478 shares during the period. Hengehold Capital Management LLC lifted its position in shares of Pfizer by 5.9% in the 2nd quarter. Hengehold Capital Management LLC now owns 87,121 shares of the biopharmaceutical company’s stock worth $3,774,000 after acquiring an additional 4,826 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Pfizer by 0.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 1,368,003 shares of the biopharmaceutical company’s stock worth $59,259,000 after acquiring an additional 10,617 shares during the period. Finally, Whittier Trust Co. lifted its position in shares of Pfizer by 1.2% in the 2nd quarter. Whittier Trust Co. now owns 557,798 shares of the biopharmaceutical company’s stock worth $24,158,000 after acquiring an additional 6,559 shares during the period. 71.81% of the stock is currently owned by institutional investors.

In other news, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the transaction, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Monday, July 29th. Morgan Stanley cut Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $48.00 to $40.00 in a report on Tuesday, July 30th. UBS Group reaffirmed a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a research note on Monday. Fourteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $46.56.

Shares of Pfizer stock opened at $34.48 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. The stock’s 50-day moving average is $41.01 and its 200-day moving average is $41.72. The firm has a market cap of $195.80 billion, a price-to-earnings ratio of 11.49, a price-to-earnings-growth ratio of 2.83 and a beta of 0.63. Pfizer Inc. has a one year low of $33.97 and a one year high of $46.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The company had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The business’s revenue was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.77 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.8 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be paid a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 4.18%. The ex-dividend date is Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Debt-To-Equity Ratio

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.